title: Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome.
abstract: OBJECTIVE
  Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS).
  
  
  METHODS
  In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA.
  
  
  RESULTS
  Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p < 0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p < 0.001). Twelve patients (22%) were taking statins. Patients on statins had a significant reduction in clinical complications (33%) versus patients not receiving statin therapy (61%). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect.
  
  
  CONCLUSIONS
  Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.
authors.affiliation: Angiology and Intensive Care Unit, Third Department of Medicine, Institute of Internal Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary. renata.laczik@gmail.com
authors.forename: R
authors.initials: R
authors.lastname: Laczik
authors.forename: P
authors.initials: P
authors.lastname: Szodoray
authors.forename: K
authors.initials: K
authors.lastname: Veres
authors.forename: E
authors.initials: E
authors.lastname: Szomják
authors.forename: I
authors.initials: I
authors.lastname: Csípo
authors.forename: S
authors.initials: S
authors.lastname: Sipka
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
authors.forename: Z
authors.initials: Z
authors.lastname: Szekanecz
authors.forename: P
authors.initials: P
authors.lastname: Soltész
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000276:immunology*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D007074:Immunoglobulin G / Q000097:blood*; D008077:Lipoproteins, LDL / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D058226:Plaque, Atherosclerotic / Q000276:immunology; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D001323:Autoantibodies; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007074:Immunoglobulin G; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein